Navigation Links
VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems
Date:3/2/2009

because of their continued focus on product quality and customer service as well as their established market leadership."

This selection extends the existing preferred vendor status Thomson Reuters has with VHA for its management decision support solutions that address clinical benchmarking, financial and operational improvement, and market planning and strategy.

"Our Clinical Xpert suite excels at providing clinicians with critical patient information at the point of care to help them improve patient safety and clinical outcomes," said Thomas Hegelund, executive vice president of the Healthcare business of Thomson Reuters. "We look forward to this relationship with VHA as we continue our efforts to help hospitals across the country measurably improve clinical performance."

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AnaptysBio Selects Gable PR of San Diego for National Communications Program During Key Phase in Growth
2. St John Ambulance Selects Web-Based SMS Solution From Text Messaging Centre (TMC) for Rapid Response Communication via Two-Way SMS Messaging
3. Pee Dee Cardiology Selects Allscripts Professional Electronic Health Record and Practice Management Solution
4. Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform
5. University HealthSystem Consortium Selects Cartus to Provide Relocation Services
6. Marshfield Clinic Selects SAP(R) BusinessObjects(TM) Solutions to Improve Patient Treatment and Clinic Management
7. Community Medical Center (Scranton) Selects SIS Perioperative Solution
8. Texcel Selects Tiziani Whitmyre for Public Relations, Internet Marketing Services
9. CMS Selects Thomson Reuters to Help Implement Medicare Medical Home Demonstration Project for Medicare Recipients
10. E-VERIFILE.COM, Inc. Selects Medium Blue Search Engine Marketing to Highlight Its Innovative Screening and Hiring Solutions with Search Engine Optimization and Online PR
11. eFoodSafety.com Selects Arcand & Madison as Public Relations Counsel and The Ruth Group as Investor Relations Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... -- A group of scientists from the University ... Center on Aging has found interesting new information ... in Parkinson,s disease (PD). , Published in ... which assessed cognitive function in depressed and non-depressed ... therapy commonly used to treat motor symptoms of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... year’s polio outbreak on the wane and excellent coverage ... Group today advised// the government that the next few ... most vulnerable children, who are not being sufficiently immunized ... and international experts who advised the government on strategies ...
... Delhi: Reliance Life Sciences, the biotechnology venture of Mukesh Ambani's ... and building// a world class manufacturing unit to produce them. ... unit due to the response to its Factor VII product, ... of Factor VII in their blood that leads to serious ...
... which happens as people catch up with age is fine, but ... have major repercussions on health, increasing the chances of early death. ... 3 centimeters or more in height of men as they age ... men who lose less than a centimeter. This risk was thought ...
... study involving more than 413,000 persons from 10 countries has ... activity or two hours// of moderate activity can cut the ... 35 per cent. ,Christine Friedenreich of the International Agency ... Cancer Board carried out the study to assess how ...
... from University of Sydney suggested that having an epidural ... breastfeeding//. The study results were published in the December ... who studied 1,300 women who gave birth between March ... anaesthetic are more likely to have problems in the ...
... India, has come up with another project. This scheme named ... to cost Rs 342.81-crores. ,The Global Fund aids ... will also be spent for reducing the transmission of HIV ... including antiretroviral therapy to those already infected. ,There ...
Cached Medicine News:Health News:Polio Outbreak on Wane: Next Rounds Must Focus on Youngest Children 2
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Strategy for ... ... SGMO ) announced today the publication of data,demonstrating that human immune ... treatment with zinc finger DNA-binding,protein nucleases (ZFN(TM)). The data suggest that ...
... mention ongoing FDA-approved HIFU clinical trials in the, ... and experience, CHARLOTTE, N.C., June 27 USHIFU, ... for prostate cancer,treatment in North and South America, announced ... featured a segment on high intensity focused,ultrasound (HIFU) for ...
Cached Medicine Technology:Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 6ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 2ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 3
1.0 mm diameter head, 0.75 mm deep bite....
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Optec vision tester....
Brightness acuity tester....
Medicine Products: